Lead
Many parents already choose "BPA-free" bottles. After the EU banned BPA (bisphenol A) from infant feeding bottles in 2011 and the US FDA followed in 2012, the Japanese market largely shifted away from the compound through a combination of voluntary manufacturer action and heightened consumer awareness. That regulatory shift had a legitimate scientific basis.
What is less widely appreciated is that the main substitutes for BPA — bisphenol S (BPS) and bisphenol F (BPF) — appear to carry similar endocrine-disrupting: interfering with the body's hormone system, which can affect growth, development, and reproduction properties, according to a systematic review published after the regulatory wave. This "regrettable substitution" problem is worth understanding alongside the broader question of what animal studies and epidemiological research do and do not tell us about endocrine-disrupting chemicals.
Why BPA was regulated — and why the regulatory story is more nuanced than it appears
BPA has been used since the 1950s as a monomer in polycarbonate plastics and epoxy resins, and it appeared in food containers, the inner coatings of food cans, and infant feeding bottles. Regulation gathered momentum because BPA binds to estrogen receptors even at very low concentrations, and animal data consistently showed endocrine-disrupting effects.
EFSA's 2015 opinion on BPA established a temporary Tolerable Daily Intake (TDI): the estimated amount of a substance that can be ingested daily over a lifetime without appreciable health risk of 4 micrograms per kilogram of body weight per day [1]. Then, in a 2023 re-evaluation, EFSA substantially lowered that TDI to 0.2 nanograms per kilogram of body weight per day — a reduction by a factor of roughly 20,000 [2]. The key shift in the 2023 evaluation was methodological: EFSA adopted effects on the immune system (specifically, effects on Th17 immune cells) as the critical endpoint, and concluded that estimated dietary exposure in most age groups — including young children — likely exceeds this revised TDI [2].
It is important to read the FDA's 2012 ban on BPA in infant bottles and sippy cups carefully. The primary stated rationale was not that BPA's toxicity had been definitively established, but that manufacturers had already discontinued BPA use in those product categories and the regulatory amendment reflected market reality. That distinction is often lost in popular accounts of the ban.
In Japan, the Food Safety Commission has conducted ongoing evaluations, and use of BPA in food contact materials is managed under technical standards set by the Ministry of Health, Labour and Welfare. The domestic market's transition away from BPA in infant bottles occurred largely through voluntary industry action around 2011–2012.
The "regrettable substitution" problem: BPS and BPF
When the market shifted away from BPA, manufacturers turned largely to BPS and BPF as structural replacements. A 2015 systematic review by Rochester and Bolden analyzed 32 studies — 25 in vitro, seven in vivo — examining the endocrine-disrupting activity of BPS and BPF [3]. Their conclusion was that both compounds display endocrine-disrupting potency comparable to that of BPA.
This is the pattern toxicologists call regrettable substitution: replacing a regulated chemical with a close relative that turns out to share the same hazards: regulating a problematic substance leads to replacement with structurally similar compounds carrying similar properties. A label reading "BPA-free" does not mean the product is free of BPS or BPF. Some BPA-free products contain BPS or BPF; the label specifies only what is absent, not what is present.
An important qualification: the data on BPS and BPF are far less extensive than the accumulated literature on BPA. Long-term human health outcome studies in infants and toddlers are limited. The weight of evidence that warranted BPA regulation does not yet exist in the same form for its substitutes — but the direction of the available findings is not reassuring.
Animal studies, epidemiology, and the gap between them
The endocrine-disrupting activity of BPA and structurally related compounds is robustly demonstrated in animal experiments [5,6]. Human epidemiological findings are considerably less consistent, and the gap between the two is a real feature of the science — not a reason to dismiss either body of evidence, but a complexity worth understanding.
Several factors explain the discordance. Experimental animals (rats, mice) receive doses orders of magnitude higher than typical human exposure. Different testing systems — in vitro cell assays, in vivo animal studies, human cohort studies — measure different endpoints, making direct comparison difficult. In human studies, controlling for confounders is challenging; causation is hard to establish cleanly.
A specific concern for infants involves the question of whether the same exposure level carries different implications in a newborn than in an adult. A newborn's kidneys are metabolically immature relative to an adult's. Multiple studies have measured BPA leaching from polycarbonate bottles into liquid at elevated temperatures, reporting levels in the range of tens to hundreds of parts per billion when boiling water is used [6]. Whether the same tissue burden in a newborn carries different downstream consequences remains an open research question — and it is precisely this concern that underlies the "infants may be more vulnerable" argument [5].
Phthalates — a different exposure route
Phthalate esters: chemical compounds added to plastics to make them flexible; some are studied for possible hormone-disrupting effects are plasticizers used to soften polyvinyl chloride (PVC) and appear in flooring, children's toys, and medical device tubing. They are regulated as endocrine-disrupting substances and have established TDIs from JECFA and EFSA for the most studied compound, DEHP (di(2-ethylhexyl) phthalate).
Phthalate exposure for infants and toddlers comes less from feeding bottles themselves and more from oral and dermal contact with PVC-containing toys and flooring, and from medical device tubing in hospital settings. Regulatory pressure on phthalates in children's products has strengthened across most major markets over the past two decades, and many product categories are now subject to specific limits.
Practical steps under uncertainty
Complete zero-exposure is not achievable, but there are practical choices that reduce exposure without requiring certainty about every downstream health effect.
- Polycarbonate bottles are now largely absent from the market, but when purchasing any bottle, checking the material specification (glass, PPSU, or polypropylene) reduces reliance on marketing language alone
- Heating bottles in microwave ovens should follow manufacturer instructions regardless of material, because some materials release more at elevated temperatures — the principle applies beyond BPA-containing plastics
- "BPA-free" should be read as "this product has excluded BPA," not as "all bisphenol concerns have been resolved"
- PVC-containing toys and flooring are an exposure route for phthalates; for young children who mouth objects extensively, material awareness is reasonable
- No material currently available offers an absolute safety guarantee. Informed, proportionate choices under conditions of incomplete information is the goal
Summary
BPA regulation was built incrementally on animal data and the precautionary principle; EFSA's 2023 re-evaluation substantially lowered the TDI and identified estimated dietary exposures as a potential concern across multiple age groups. Substitute bisphenols (BPS, BPF) display comparable endocrine-disrupting activity in the available systematic review evidence, meaning "BPA-free" does not constitute a comprehensive solution. The animal–epidemiology gap persists, and the long-term effects of early infant exposure remain an active research area. Phthalate exposure in young children comes primarily through PVC toys and flooring rather than bottles. The practical response is reading material labels, avoiding high-temperature heating where possible, and maintaining a proportionate view of what each label claim does and does not cover.
References
- European Food Safety Authority. Scientific Opinion on the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs. EFSA Journal. 2015;13(1):3978. doi:10.2903/j.efsa.2015.3978.
- European Food Safety Authority. Re-evaluation of the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs. EFSA Journal. 2023;21(4):e06857. doi:10.2903/j.efsa.2023.6857.
- Rochester JR, Bolden AL. Bisphenol S and F: A Systematic Review and Comparison of the Hormonal Activity of Bisphenol A Substitutes. Environ Health Perspect. 2015;123(7):643–650. doi:10.1289/ehp.1408989. PMID: 25775505.
- Ye X, Wong LY, Kramer J, Zhou X, Jia T, Calafat AM. Urinary Concentrations of Bisphenol A and Three Other Bisphenols in Convenience Samples of U.S. Adults during 2000–2014. Environ Sci Technol. 2015;49(19):11834–11839. PMID: 26360019. [unverified: Japanese draft listed "Ye X, Wong LY, Kruse RL, Calafat AM" with year range 2000–2016 and no PMID; PubMed search identified PMID 26360019 with corrected author list and year range 2000–2014]
- Vandenberg LN, Maffini MV, Sonnenschein C, Rubin BS, Soto AM. Bisphenol-A and the Great Divide: A Review of Controversies in the Field of Endocrine Disruption. Endocr Rev. 2009;30(1):75–95. doi:10.1210/er.2008-0021. PMID: 19074586.
- Talsness CE, Andrade AJM, Kuriyama SN, Taylor JA, vom Saal FS. Components of plastic: experimental studies in animals and relevance for human health. Philos Trans R Soc B Biol Sci. 2009;364(1526):2079–2096. doi:10.1098/rstb.2008.0281. PMID: 19528057.